Get the Stockscreener App
0.39
1.30%
0.005
After Hours:
.38
-0.01
-2.56%
Mersana Therapeutics Inc stock is traded at $0.39, with a volume of 2.48M.
It is up +1.30% in the last 24 hours and up +9.95% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$0.385
Open:
$0.3834
24h Volume:
2.48M
Relative Volume:
0.81
Market Cap:
$48.61M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-0.26
EPS:
-1.5
Net Cash Flow:
$-171.05M
1W Performance:
+8.88%
1M Performance:
+9.95%
6M Performance:
-82.43%
1Y Performance:
-85.92%
1-Day Range:
$0.3573
$0.39
1-Week Range:
$0.303
$0.424
52-Week Range:
$0.2589
$2.83
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.39 | 44.64M | 36.86M | -171.67M | -171.05M | -1.50 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Mersana Therapeutics to Present at Upcoming Investor Conferences | MRSN Stock News - GuruFocus
Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus
Mersana Therapeutics (MRSN) Target Price Increased by Truist | MRSN Stock News - GuruFocus
Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com
Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria
Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com
Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan
Mersana Therapeutics (MRSN) Reports Lower Q1 Revenue and Shares - GuruFocus
Mersana Therapeutics Provides Business Update and Announces Firs - GuruFocus
Mersana Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results - GlobeNewswire
Clinical Trial Results: Mersana's New Cancer Drug Achieves 31% Response Rate in Hard-to-Treat Tumors - Stock Titan
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Barclays PLC Sells 311,805 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Wedbush Expects Stronger Earnings for Mersana Therapeutics - Defense World
Petri Dish: Cancer biotech cuts staff; Lantheus sells business unit - The Business Journals
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Wedbush Cuts Price Target on Mersana Therapeutics to $3 From $4, Maintains Outperform Rating - marketscreener.com
Mersana Therapeutics announces restructuring plans; shares fall - TradingView
Mersana Therapeutics Announces Restructuring and Reprioritization Plan - citybiz
Mersana Therapeutics (MRSN) Announces Major Restructuring Strate - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Repri - GuruFocus
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer | MRSN Stock News - GuruFocus
Mersana Therapeutics announces strategic cutbacks amid economic pressures - Investing.com
Mersana Therapeutics Announces Strategic Restructuring to Extend Cash Runway and Focus on Emi-Le Development - Nasdaq
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer - GlobeNewswire
Mersana Slashes Workforce by 55%, Doubles Down on Promising Breast Cancer Drug Pipeline - Stock Titan
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Mersana Therapeutics Inc [MRSN] stock for 2,061 USD was sold by Mandelia Ashish - knoxdaily.com
Renaissance Technologies LLC Has $867,000 Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc (MRSN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Mersana Therapeutics (MRSN) Expected to Announce Earnings on Thursday - Defense World
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):